ERG245
Product Specifications
Target
Others
Related Pathways
Others
Bioactivity
ERG245 is a BCAT1 inhibitor that promotes oxidative phosphorylation (OXPHOS) in CD8+ T cells by selectively inhibiting the enzymatic activity of BCAT1, thereby increasing the cytotoxic capacity of CD8+ T cells. ERG245, when administered in combination with the anti-PD-1 antibody Pembrolizumab, induces tumor regression in preclinical settings, and it can be used as a research agent within the field of immuno-oncology.
Smiles
BrC1=CC=C(C(C(C2=CC=CC=C2)CCC(O)=O)=O)C=C1
Molecular Formula
C17H15BrO3
Molecular Weight
347.2
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1259318-01 0.02 mg (E-Coli)
Recombinant Salmonella typhimurium Secretion system apparatus protein ssaL (ssaL)
Ask
View Details MBS1259318-02 0.02 mg (Yeast)
Recombinant Salmonella typhimurium Secretion system apparatus protein ssaL (ssaL)
Ask
View Details MBS1259318-03 0.1 mg (E-Coli)
Recombinant Salmonella typhimurium Secretion system apparatus protein ssaL (ssaL)
Ask
View Details 
MBS1259318-04 0.1 mg (Yeast)
Recombinant Salmonella typhimurium Secretion system apparatus protein ssaL (ssaL)
Ask
View Details 
MBS1259318-05 0.02 mg (Baculovirus)
Recombinant Salmonella typhimurium Secretion system apparatus protein ssaL (ssaL)
Ask
View Details